{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:21:30Z","timestamp":1760188890183},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s11910-005-0062-8","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T13:15:56Z","timestamp":1181049356000},"page":"382-388","source":"Crossref","is-referenced-by-count":13,"title":["Visual aspects of Beh\u00c7et\u2019s disease"],"prefix":"10.1007","volume":"5","author":[{"given":"Tulay","family":"Kansu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Kadayifcilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"62_CR1","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00c7et\u2019s disease","year":"1990","unstructured":"International Study Group for Beh\u00c7et\u2019s disease: Criteria for diagnosis of Beh\u00c7et\u2019s disease. Lancet 1990, 335:1078\u20131080.","journal-title":"Lancet"},{"key":"62_CR2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/bjo.87.9.1175","volume":"87","author":"DH Verity","year":"2003","unstructured":"Verity DH, Wallace GR, Vaughan RW, Stanford MR: Beh\u00c7et\u2019s disease: from Hippocrates to the third millennium. Br J Ophthalmol 2003, 87:1175\u20131183. An extensive review with a historical perspective and new insights into the genetic basis of BD.","journal-title":"Br J Ophthalmol"},{"key":"62_CR3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2003.07.018","volume":"111","author":"A Yoshida","year":"2004","unstructured":"Yoshida A, Kawashima H, Motoyama Y, et al.: Comparison of patients with Behcet\u2019s disease in the 1980s and 1990s. Ophthalmology 2004, 111:810\u2013815.","journal-title":"Ophthalmology"},{"key":"62_CR4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al.: Uveitis in Beh\u00c7et\u2019s disease: an analysis of 880 patients. Am J Ophthalmol 2004, 138:373\u2013380. A report from a center with vast experience in BD reviewing their findings on uveitis in BD with a comparison of patients presenting in 1980s and 1990s.","journal-title":"Am J Ophthalmol"},{"key":"62_CR5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3928\/0191-3913-20031101-06","volume":"40","author":"S Kadayifcilar","year":"2003","unstructured":"Kadayifcilar S, Eldem B, Tumer B: Uveitis in childhood. J Pediatr Ophthalmol Strabismus 2003, 40:335\u2013340.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"62_CR6","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0002-9394(03)00791-8","volume":"136","author":"I Tugal-Tutkun","year":"2003","unstructured":"Tugal-Tutkun I, Urgancioglu M: Childhood-onset uveitis in Beh\u00c7et\u2019s disease: A descriptive study of 36 cases. Am J Ophthalmol 2003, 136:1114\u20131119.","journal-title":"Am J Ophthalmol"},{"key":"62_CR7","first-page":"309","volume":"51","author":"J Rohatgi","year":"2003","unstructured":"Rohatgi J, Singal A: Ocular manifestations of Beh\u00c7et\u2019s disease in Indian patients. Indian J Ophthalmol 2003, 51:309\u2013313.","journal-title":"Indian J Ophthalmol"},{"key":"62_CR8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0161-6420(03)00265-3","volume":"110","author":"E Zamir","year":"2003","unstructured":"Zamir E, Bodaghi B, Tugal-Tutkun I, et al.: Conjunctival ulcers in Beh\u00c7et\u2019s disease. Ophthalmology 2003, 110:1137\u20131141.","journal-title":"Ophthalmology"},{"key":"62_CR9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0886-3350(01)01023-9","volume":"28","author":"S Kadayifcilar","year":"2002","unstructured":"Kadayifcilar S, Gedik S, Eldem B, Irkec M: Cataract surgery in patients with Beh\u00c7et\u2019s disease. J Cataract Refract Surg 2002, 28:316\u2013320.","journal-title":"J Cataract Refract Surg"},{"key":"62_CR10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3928\/1542-8877-20040501-08","volume":"35","author":"N Berker","year":"2004","unstructured":"Berker N, Soykan E, Elgin U, Ozkan SS: Phacoemulsification cataract extraction and intraocular lens implantation in patients with Beh\u00c7et\u2019s disease. Ophthalmic Surg Lasers Imaging 2004, 35:215\u2013218.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"62_CR11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00061198-200412000-00002","volume":"13","author":"U Elgin","year":"2004","unstructured":"Elgin U, Berker N, Batman A: Incidence of secondary glaucoma in Beh\u00c7et\u2019s disease. J Glaucoma 2004, 13:441\u2013444.","journal-title":"J Glaucoma"},{"key":"62_CR12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/01.ijg.0000146624.31345.33","volume":"13","author":"IS Yalvac","year":"2004","unstructured":"Yalvac IS, Sungur G, Turhan E, et al.: Trabeculectomy with mitomycin C in uveitic glaucoma associated with Beh\u00c7et\u2019s disease. J Glaucoma 2004, 13:450\u2013453.","journal-title":"J Glaucoma"},{"key":"62_CR13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/112067210201200514","volume":"12","author":"PC Ozdal","year":"2002","unstructured":"Ozdal PC, Ortac S, Taskintuna I, Firat E: Posterior segment involvement in ocular Beh\u00c7et\u2019s disease. Eur J Ophthalmol 2002, 12:424\u2013431. A review of posterior segment findings in a large series including 131 cases. The most common finding was vitritis, which was present in 239 (93%) eyes.","journal-title":"Eur J Ophthalmol"},{"key":"62_CR14","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/S0161-6420(03)00658-4","volume":"110","author":"H Inomata","year":"2003","unstructured":"Inomata H, Yoshikowa H, Rao NA: Phacoanaphylaxis in Beh\u00c7et\u2019s disease. A clinical and immunohistochemical study. Ophthalmology 2003, 110:1942\u20131945. Twenty-eight enucleated globes from patients with BD were investigated for immunohistochemical aspects. Tractional retinal detachment was found in 23 eyes. Eight of the eyes showed phacoanaphylaxis.","journal-title":"Ophthalmology"},{"key":"62_CR15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9394(03)00110-7","volume":"136","author":"PK Rabiah","year":"2003","unstructured":"Rabiah PK, Vitale AT: Noninfectious uveitis and pregnancy. Am J Ophthalmol 2003, 136:91\u201398.","journal-title":"Am J Ophthalmol"},{"key":"62_CR16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/112067210401400623","volume":"14","author":"N Yalcindag","year":"2004","unstructured":"Yalcindag N, Yilmaz N, Tekeli O, Ozdemir O: Acute optic neuropathy in Beh\u00c7et\u2019s disease. Eur J Ophthalmol. 2004, 14:578\u2013580.","journal-title":"Eur J Ophthalmol."},{"key":"62_CR17","first-page":"9","volume":"289","author":"H Lamari","year":"2003","unstructured":"Lamari H, Baha AT, Benhaddou M, et al.: Involvement of the optic nerve in the course of Beh\u00c7et\u2019s disease (presentation of 148 cases) Bull Soc Belge Ophthalmol 2003, 289:9\u201314.","journal-title":"Bull Soc Belge Ophthalmol"},{"key":"62_CR18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00019052-200406000-00017","volume":"17","author":"A Siva","year":"2004","unstructured":"Siva A, Altintas A, Saip S: Beh\u00c7et\u2019s syndrome and the nervous system. Curr Opin Neurol 2004, 17:347\u2013357. An extensive review on neurologic involvement in BD with emphasis on recent clinical concepts and etiopathogenesis.","journal-title":"Curr Opin Neurol"},{"key":"62_CR19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1034\/j.1600-0404.2003.00019.x","volume":"108","author":"MD Aydin","year":"2003","unstructured":"Aydin MD, Aydin N: A neuro-Beh\u00c7et\u2019s lesion in oculomotor nerve nucleus. Acta Neurol Scand 2003, 108:139\u2013141.","journal-title":"Acta Neurol Scand"},{"key":"62_CR20","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/1529-0131(200111)44:11<2693::AID-ART449>3.0.CO;2-M","volume":"44","author":"A Gul","year":"2001","unstructured":"Gul A, Hajeer AH, Worthington J, et al.: Linkage mapping of a novel susceptibility locus for Beh\u00c7et\u2019s disease to chromosome 6p22-23. Arthritis Rheum 2001, 44:2693\u20132696.","journal-title":"Arthritis Rheum"},{"key":"62_CR21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11926-003-0066-9","volume":"5","author":"H Yazici","year":"2003","unstructured":"Yazici H: Beh\u00c7et\u2019s syndrome: an update. Curr Rheumatol Rep 2003, 5:195\u2013199. An expert\u2019s view on the current developments in BD.","journal-title":"Curr Rheumatol Rep"},{"key":"62_CR22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/0-306-48382-3_40","volume":"528","author":"S Beck","year":"2003","unstructured":"Beck S: The Human Genome Project: what we have learnt about the MHC region on chromosome 6 and its potential to Beh\u00c7et\u2019s disease. Adv Exp Med Biol 2003, 528:207\u2013211.","journal-title":"Adv Exp Med Biol"},{"key":"62_CR23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/rheumatology\/keh561","volume":"44","author":"JA Karasneh","year":"2005","unstructured":"Karasneh JA, Hajeer AH, Silman A, et al.: Polymorphisms in the endothelial nitric oxide synthase gene are associated with Beh\u00c7et\u2019s disease. Rheumatology 2005, 44:614\u2013617.","journal-title":"Rheumatology"},{"issue":"4 Suppl","key":"62_CR24","first-page":"S15","volume":"21","author":"J Duymaz-Tozkir","year":"2003","unstructured":"Duymaz-Tozkir J, Gul A, Uyar FA, et al.: Tumour necrosis factor-alpha gene promoter region -308 and \u2022376 G\u2192A polymorphisms in Beh\u00c7et\u2019s disease. Clin Exp Rheumatol 2003, 21(4 Suppl30):S15-S18.","journal-title":"Clin Exp Rheumatol"},{"key":"62_CR25","first-page":"93","volume":"32","author":"J Duymaz-Tozkir","year":"2005","unstructured":"Duymaz-Tozkir J, Yilmaz V, Uyar FA, et al.: Polymorphisms of the IL-8 and CXCR2 genes are not associated with Beh\u00c7et\u2019s disease. J Rheumatol 2005, 32:93\u201397.","journal-title":"J Rheumatol"},{"key":"62_CR26","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/ard.2003.014241","volume":"63","author":"M Leiba","year":"2004","unstructured":"Leiba M, Seligsohn U, Sidi Y, et al.: Thrombophilic factors are not the leading cause of thrombosis in Beh\u00c7et\u2019s disease. Ann Rheum Dis 2004, 63:1445\u20131449.","journal-title":"Ann Rheum Dis"},{"key":"62_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00001721-200302000-00001","volume":"14","author":"A Gurgey","year":"2003","unstructured":"Gurgey A, Balta G, Boyvat A: Factor V Leiden mutation and PAI-1 gene 4G\/5G genotype in thrombotic patients with Beh\u00c7et\u2019s disease. Blood Coagul Fibrinolysis 2003, 14:121\u2013124.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"62_CR28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1034\/j.1600-0420.2003.00068.x","volume":"81","author":"F Batioglu","year":"2003","unstructured":"Batioglu F, Atmaca LS, Karabulut HG, Beyza Sayin D: Factor V Leiden and prothrombin gene G20210A mutations in ocular Beh\u00c7et disease. Acta Ophthalmol Scand 2003, 81:283\u2013285.","journal-title":"Acta Ophthalmol Scand"},{"key":"62_CR29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/art.20237","volume":"51","author":"M Silingardi","year":"2004","unstructured":"Silingardi M, Salvarani C, Boiardi L, et al.: Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Beh\u00c7et\u2019s disease and deep vein thrombosis. Arthritis Rheum 2004, 51:177\u2013183.","journal-title":"Arthritis Rheum"},{"key":"62_CR30","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1515\/CCLM.2004.263","volume":"42","author":"M Feki","year":"2004","unstructured":"Feki M, Houman H, Ghannouchi M, et al.: Hyperhomocysteinaemia is associated with uveitis but not with deep venous thrombosis in Behcet\u2019s disease. Clin Chem Lab Med 2004, 42:1417\u20131423.","journal-title":"Clin Chem Lab Med"},{"key":"62_CR31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2003.12.010","volume":"137","author":"K Probst","year":"2004","unstructured":"Probst K, Fijnheer R, Rothova A: Endothelial cell activation and hypercoagulability in ocular Beh\u00c7et\u2019s disease. Am J Ophthalmol 2004, 137:850\u2013857. A cross-sectional study depicting a generalized hypercoagulable state in ocular BD regardless of current ocular disease activity.","journal-title":"Am J Ophthalmol"},{"key":"62_CR32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10067-003-0853-8","volume":"23","author":"MA Ozturk","year":"2004","unstructured":"Ozturk MA, Calguneri M, Kiraz S, et al.: Angiotensinconverting enzyme gene polymorphism in Beh\u00c7et\u2019s disease. Clin Rheumatol 2004, 23:142\u2013146.","journal-title":"Clin Rheumatol"},{"key":"62_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1076\/ocii.12.1.53.28062","volume":"12","author":"Y Bardak","year":"2004","unstructured":"Bardak Y, Aridogan BC: The demonstration of serum interleukin 6\u20138, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Beh\u00c7et\u2019s disease with ocular involvement. Ocul Immunol Inflamm 2004, 12:53\u201358.","journal-title":"Ocul Immunol Inflamm"},{"key":"62_CR34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00417-003-0668-y","volume":"241","author":"T Kaburaki","year":"2003","unstructured":"Kaburaki T, Fujino Y, Kawashima H, et al.: Plasma and wholeblood chemokine levels in patients with Behcet\u2019s disease. Graefes Arch Clin Exp Ophthalmol 2003, 241:353\u2013358.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"62_CR35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2249.2004.02536.x","volume":"137","author":"HG Yu","year":"2004","unstructured":"Yu HG, Lee DS, Seo JM, et al.: The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Beh\u00c7et\u2019s uveitis. Clin Exp Immunol 2004, 137:437\u2013443.","journal-title":"Clin Exp Immunol"},{"key":"62_CR36","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1136\/bjo.87.12.1466","volume":"87","author":"LS Atmaca","year":"2003","unstructured":"Atmaca LS, Sonmez PA: Fluorescein and indocyanine green angiography findings in Beh\u00c7et\u2019s disease. Br J Ophthalmol 2003, 87:1466\u20131468.","journal-title":"Br J Ophthalmol"},{"key":"62_CR37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/09273940490518757","volume":"13","author":"S Gedik","year":"2005","unstructured":"Gedik S, Akova Y, Yilmaz G, Bozbeyoglu S: Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Beh\u00c7et\u2019s disease. Ocul Immunol Inflamm 2005, 13:51\u201358.","journal-title":"Ocul Immunol Inflamm"},{"key":"62_CR38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/B:INTE.0000018548.82675.1b","volume":"25","author":"AJ Klaeger","year":"2004","unstructured":"Klaeger AJ, Tran VT, Hiroz CA, et al.: Use of ultrasound biomicroscopy, indocyanine green angiography and HLA-B51 testing as adjunct methods in Beh\u00c7et\u2019s uveitis. Int Ophthalmol 2004, 25:47\u201363.","journal-title":"Int Ophthalmol"},{"key":"62_CR39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajo.2004.02.053","volume":"138","author":"M Karacorlu","year":"2004","unstructured":"Karacorlu M, Mudun B, Ozdemir H, et al.: Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Beh\u00c7et\u2019s disease. Am J Ophthalmol 2004, 138:289\u2013291.","journal-title":"Am J Ophthalmol"},{"key":"62_CR40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.eye.6700556","volume":"18","author":"O Tekeli","year":"2004","unstructured":"Tekeli O, Ozdemir O: Heidelberg retina tomograph in ocular Beh\u00c7et\u2019s disease. Eye 2004, 18:143\u2013146.","journal-title":"Eye"},{"key":"62_CR41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bjo.86.5.521","volume":"86","author":"E Toker","year":"2002","unstructured":"Toker E, Kazokoglu H, Acar N: High dose intravitreal steroid therapy for severe posterior segment uveitis in Beh\u00c7et\u2019s disease. Br J Ophthalmol 2002, 86:321\u2013323.","journal-title":"Br J Ophthalmol"},{"key":"62_CR42","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ajo.2004.04.064","volume":"138","author":"M Kramer","year":"2004","unstructured":"Kramer M, Ehrlich R, Snir M, et al.: Intravitreal injection of triamcinolone acetonide for severe vitritis in patients with incomplete Beh\u00c7et\u2019s disease. Am J Ophthalmol 2004, 138:666\u2013667.","journal-title":"Am J Ophthalmol"},{"key":"62_CR43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1021227019915","volume":"105","author":"PC Ozdal","year":"2002","unstructured":"Ozdal PC, Ortac S, Taskintuna I, Firat E: Long term therapy with low dose cyclosporin A in ocular Beh\u00c7et\u2019s disease. Doc Ophthalmol 2002, 105:301\u2013312.","journal-title":"Doc Ophthalmol"},{"key":"62_CR44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I Kotter","year":"2003","unstructured":"Kotter I, Zierhut M, Eckstein AK, et al.: Human recombinant interferon-_2a for the treatment of Beh\u00c7et\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003, 87:423\u2013431. This paper describes positive experience with interferon-\u00e1 in treatment of patients with BD; however, the study was uncontrolled and nonrandomized.","journal-title":"Br J Ophthalmol"},{"key":"62_CR45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00347-003-0927-7","volume":"101","author":"CM Deuter","year":"2004","unstructured":"Deuter CM, Kotter I, Gunaydin I, et al.: Ocular involvement in Beh\u00c7et\u2019s disease: first 5-year-results for visual development after treatment with interferon alpha-2a. Ophthalmologe 2004, 101:129\u2013134.","journal-title":"Ophthalmologe"},{"key":"62_CR46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","volume":"33","author":"I Kotter","year":"2004","unstructured":"Kotter I, Vonthein R, Zierhut M, et al.: Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Beh\u00c7et\u2019s disease. Semin Arthritis Rheum 2004, 33:311\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"62_CR47","first-page":"14","volume":"22","author":"B Wechsler","year":"2004","unstructured":"Wechsler B, Sable-Fourtassou R, Bodaghi B, et al.: Infliximab in refractory uveitis due to Beh\u00c7et\u2019s disease. Clin Exp Rheumatol 2004, 22:14\u201316.","journal-title":"Clin Exp Rheumatol"},{"key":"62_CR48","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210401400515","volume":"14","author":"F Giansanti","year":"2004","unstructured":"Giansanti F, Barbera ML, Virgili G, et al.: Infliximab for the treatment of posterior uveitis with retinal neovascularization in Beh\u00c7et disease. Eur J Ophthalmol 2004, 14:445\u2013458.","journal-title":"Eur J Ophthalmol"},{"key":"62_CR49","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, et al.: Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Beh\u00c7et\u2019s disease with refractory uveoretinitis. J Rheumatol 2004, 31:1362\u20131368. The authors report the largest experience in this new treatment that seems to be effective in severely affected patients who do not respond to conventional therapies.","journal-title":"J Rheumatol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-005-0062-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-005-0062-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-005-0062-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:24:34Z","timestamp":1559435074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-005-0062-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["62"],"URL":"https:\/\/doi.org\/10.1007\/s11910-005-0062-8","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}